Abstract: A modular LED array light source comprises an assembly of a plurality of solid-state LED array modules. Modules are abutted to provide a large area, high intensity and high-density array that provides substantially uniform irradiance. Preferably, in each module, a linear or rectangular array of groups of LED is provided in which the density of LED die in the array is higher at ends or edges of the modules abutting other modules, to provide improved uniformity of irradiance over the illuminated area between modules. Particular arrangements of clusters of LEDs are provided that reduce or overcome the discontinuity or dip in irradiance due to edge or wall effects caused by the spacing of LED die from edges of the substrate/packaging of each module. These arrangements are advantageous for hermetically sealed LED array modules, for example, which require a minimum wall thickness for an effective seal.

Abstract: A modular LED array light source comprises an assembly of a plurality of solid-state LED array modules. Modules are abutted to provide a large area, high intensity, and high-density array that provides substantially uniform irradiance. Preferably, in each module, a linear or rectangular array of groups of LED is provided in which the density of LED die in the array is higher at ends or edges of the modules abutting other modules, to provide improved uniformity of irradiance over the illuminated area between modules. Particular arrangements of clusters of LEDs are provided that reduce or overcome the discontinuity or dip in irradiance due to edge or wall effects caused by the spacing of LED die from edges of the substrate/packaging of each module. These arrangements are advantageous for hermetically sealed LED array modules, for example, which require a minimum wall thickness for an effective seal.

Abstract: The present invention relates methods and compositions for treating interleukin-17 (IL-17) related conditions, such as IL-17A or IL-17F, or muteins thereof in patients having fibrosis using IL-17 antagonists, such as small molecule IL-17 antagonists or protein IL-17 antagonists, such as antibodies, including specified portions or variants, specific for at least one IL-17 protein, mutein or fragment thereof, including therapeutic formulations, administration and devices.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.

Abstract: The invention encompasses methods and compositions for increasing or decreasing collagen 1A1 expression and/or ?-smooth muscle actin expression in lung fibroblasts using SERPINE2 and antagonists of SERPINE2. The invention also encompasses methods and compositions for increasing or decreasing the formation of myofibroblasts. The invention further provides methods and compositions for treatment of lung diseases, such as idiopathic pulmonary fibrosis and chronic obstructive pulmonary disease.

Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Antigens useful for raising antibodies against human resistin are also disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Methods of utilizing resistin as a biomarker to diagnose the risk and/or progression of osteoarthritis are also disclosed. Further disclosed are methods of utilizing the antagonists to treat or alleviate the symptoms of osteoarthritis.

Abstract: Resistin antagonists, including antibodies reactive with defined epitopes, are disclosed. Methods of utilizing resistin antagonists to treat or alleviate the symptoms of the diseases with aberrant fibroblast activity including interstitial lung diseases, hypertrophic scarring, keloid scarring and scleroderma are also disclosed. Antigens useful for raising antibodies against human resistin are also disclosed.

Abstract: The present invention provides a toolholder mountable on a lathe or other machine tool for supporting a cutting plate relative to a workpiece for cutting or shaping the workpiece. The toolholder including a body having a tapered tool base at one end thereof, the tool base defining a tool seat for supporting a cutting plate. A plug screw having a head defining threads on an outer surface thereof for engaging a threaded hole in the tool base is also provided. The plug screw further defining a shank extending eccentrically from the head, the shank being receivable through a mounting hole defined by the cutting plate for locating the cutting plate relative to the tool seat upon rotation of the plug screw relative to the tool base. A lock nut is provided for receiving a threaded end of the shank for securing the cutting plate to the tool base and toolholder.

Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

Abstract: The present invention provides a new subcutaneous injection dosing regimen for erythropoietin to treat anemia. The new erythropoietin treatment regimen of the present invention results in improved hemoglobin levels with less frequent dosing.

Abstract: The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.

Abstract: A modified bone morphogenetic protein (BMP, also referred to as bone morphogenic protein) composition is described. The bone morphogenetic protein, in one embodiment, is BMP-7 which is chemically modified with a hydrophilic polymer, such as poly(ethylene glycol).

Abstract: The effect of EPO on the phosphorylation of the EPO receptor, the activation of the MAP Kinase pathway, and the expression of SHP-1 were analyzed. EPO was observed to cause a decrease in the expression of its negative regulator SHP-1. The decrease observed at both the mRNA and protein level was dose dependent and persisted as long as 24 hr following EPO treatment. EPO can down regulate the expression of its own negative regulator as a means for increased potency in neurons. Assays were generated to identify compounds that are useful in regulating SHP1 activity in neural cells.

Abstract: A novel class of compounds has been identified that inhibit PTP-1B through a newly discovered binding interaction. Methods of treating, preventing or delaying the onset of, conditions mediated by PTP-1B are also provided. The compounds are capable of interacting with the primary binding pocket of PTP-1B via a hydrogen bond acceptor and have an aqueous phase free energy more positive than about ?1200 kJ/mol. Representative compounds in the class are those of Formula I: or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug or metabolite form, or a pharmaceutically acceptable salt thereof, wherein R1, R2 and/or R3 are independently hydrogen atoms or alkyl groups and G1 and G2 are aryl, heteroaryl, alkyl, arylalkanyl, arylalkenyl, arylalkynyl, heteroarylalkanyl, heteroarylalkenyl, or heteroarylalkynyl moieties.

Abstract: The present invention demonstrates EPO's efficacy in promoting patient recovery following an ischemic event. The invention demonstrates that a longer window of opportunity exists for the initial uses of EPO in treating ischemic stroke than had been previously been understood.

Abstract: The present invention provides a new subcutaneous injection dosing regimen for erythropoietin to treat anemia. The new erythropoietin treatment regimen of the present invention results in improved hemoglobin levels with less frequent dosing.

Abstract: Methods of treating diseases of the nervous system by administration of compositions having the neurological therapeutic activity of human erythropoietin are disclosed. These compositions include therapeutic agents such as peptides, peptide dimers, polypeptides, and proteins that have the full range of biological activity of human erythropoietin or only certain biological activities of erythropoietin. Improved therapeutic regimens where the erythropoietin is administered at concentrations below those required to stimulate hematopoiesis are also provided.

Abstract: The present invention provides, in one embodiment, methods to treat, prevent the progression of, or facilitate elimination of a malignancy by increasing the supply of red blood cells using erythropoietin in conjunction with administration of an anti-tumor agent.